2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases

(2020) Lisa R. Sammaritano et al.   ARTHRITIS CARE & RESEARCH

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial

(2020) Ronald van Vollenhoven et al.   Arthritis & Rheumatology

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

(2020) Andrea Rubbert-Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty

(2019) Michael D. George et al.   ANNALS OF INTERNAL MEDICINE

2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures

(2019) Bryant R. England et al.   ARTHRITIS CARE & RESEARCH

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

Low Persistence Rates in Rheumatoid Arthritis Patients Treated with Triple Therapy are Attributed to Adverse Drug Events Associated with Sulfasalazine

(2018) Daniel P. Erhardt et al.   ARTHRITIS CARE & RESEARCH

How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies

(2018) Sytske Anne Bergstra et al.   ANNALS OF THE RHEUMATIC DISEASES

The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life

(2018) I.C. Scott et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access

(2017) Karel Pavelka et al.   RHEUMATOLOGY INTERNATIONAL

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis

(2017) Brian C. Sauer et al.   ARTHRITIS CARE & RESEARCH

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

(2017) Susan M. Goodman et al.   Arthritis & Rheumatology

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers

(2016) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

(2016) P Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance

(2016) Paul E. Alexander et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies: Table 1

(2016) Johannes W. J. Bijlsma et al.   RHEUMATOLOGY

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial

(2016) Marjan Ghiti Moghadam et al.   Arthritis & Rheumatology

Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area

(2016) Tsai-Ling Liao et al.   Scientific Reports

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

(2015) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased risk of mycobacterial infections associated with anti-rheumatic medications

(2015) S. K. Brode et al.   THORAX

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis

(2015) Liana Fraenkel et al.   ARTHRITIS CARE & RESEARCH

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

(2014) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

(2014) Michael H Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength

(2013) Jeffrey C. Andrews et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review

(2013) Camille Roubille et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis

(2013) Inmaculada del Rincón et al.   Arthritis & Rheumatology

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis

(2012) William G Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Mycobacterial diseases and antitumour necrosis factor therapy in USA

(2012) KL Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

AGREE II: advancing guideline development, reporting and evaluation in health care

(2010) M. C. Brouwers et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab

(2010) Shin-ya Kawashiri et al.   RHEUMATOLOGY INTERNATIONAL

Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

(2009) Hirofumi Taki et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

(2008) W Katchamart et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

Dose-related patterns of glucocorticoid-induced side effects

(2008) D Huscher et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

(2008) Diane Lacaille et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate

(2008) Rachelle Buchbinder et al.   ARTHRITIS AND RHEUMATISM

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal